BARDA highlights Tiba in a new FASTx program to accelerate the development of early-stage antiviral platforms with multiple collaborators
Tiba announces a BARDA FASTx award to develop an RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein using Tiba’s novel RNABL™ delivery platform
The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.
Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’), to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.
CEPI highlights progress toward a new generation of vaccines
January 15, 2024
Tiba Biotech was mentioned in the recent edition of THE VIRAL MOST WANTED, a series of articles by the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting progress toward the development of next generation flavivirus vaccines.
NIH awards Tiba a Phase II SBIR grant to advance RNA vaccines against pandemic influenza
September 5, 2023
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
This article, appearing in Scrip’s Tech Transfer Roundup, reports on Tiba Biotech and CEPI planning ahead for the next pandemic.
Pour nos ami(e)s francophones, voici un reportage sur le parteneriat entre CEPI et Tiba Biotech.
CEPI Assessing Advanced RNA Nanoparticle Vaccine
January 23, 2023
The partnership between CEPI and Tiba Biotech is the focus of this article in Science & Enterprise.
Precision Vaccinations reports on CEPI and Tiba Biotech’s partnership to evaluate next-generation RNA vaccine platform technology.
Keep connected with us
© 2024 Tiba Biotech LLC. All rights reserved